Privacy voorkeur

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


EAHAD 2016: Highlight 3 – Musculoskeletal complications

In highlight three, mobility takes the center stage. With hemophilia patient reaching advanced ages, is has become apparent that they have a higher chance of developing osteoporosis. The reasons and treatments of this complications will be explained to you. Other subjects include a new approach to treating inflammation during a joint bleed and joint outcomes in mild hemophilia patients.

Speakers:

  • Prof. Alok Srivastava, MD, Christian Medical College, Vellore: Low dose prophylaxis and treatment of joint inflammation caused by joint bleeds
  • Mehdi Osooli, M.Sc., Lund University: Joint outcomes in mild hemophilia: a register based study
  • Björn Rosengren, MD PhD, Skåne University Hospital, Malmö: Managing osteoporosis in hemophilia patients
  • This program is editorially independent and is financially made possible by

Related items

Congress news

EAHAD 2016: Highlight 2 – Hemophilia A

This highlight is dedicated to hemophilia A. The latest updates of the SIPPET, FranceCoag en RODIN studies are presented and we cover original research. You will learn about PDI, a molecule that might (partly) explain variations in bleeding phenotypes. Also, the value of the TGA test is discussed. The highlight ends with a case discussion, which stresses the importance of a multidisciplinary approach and serves to explain the treatment of inhibitors with ITI. Speakers: Elena Santagostino, MD PhD, Maggiore Hospital Policlinico, Milan: TGA for testing of hemostatic effectiveness of fVIII concentrates in patients with Hemophilia A and inhibitors: in vitro results from the predicTGA study Prof. Cédric Hermans, MD, St-Luc University Hospital, Brussels: Updates on the SIPPET, FranceCoag and RODIN studies: the relationship between specific FVIII concentrate and inhibitor formation Katharina Holstein, MD, University Medical Centre, Hamburg: Expression and release of platelet protein disulfide isomerase (PDI) is increased in patients with hemophilia A Prof. Karin Fijnvandraat, MD, Academisch Medisch Centrum, Amsterdam: Case report - Multidisciplinary approach, treatment of inhibitors with ITI

Congress news

EAHAD 2016: Highlight 1 – Von Willebrand Disease

Two original studies will be covered in the first highlight. In addition, the elements and usefulness of a VWD classification system are discussed. The presenting authors explain why it is important to restage VWD patients using current guidelines, and a controversial topic is breeched: can some VWD2B patients be treated with desmopressin prophylaxis before minor surgery, instead of FVIII concentrate, based on their genotype? Speakers: Carolyn Millar, MD, Hammersmith Hospital, London: The necessity of VWD subclassification Vuokko Jokela, MD, Helsinki University Central Hospital: Impact of platelet function on clinical phenotypes in Von Willebrand Disease: re-evaluation of 83 patient with historical diagnosis Lucia Rugeri, MD, Hôpital Cardiologique, Lyon: Genotyping might help therapeutic decision making in patients with Von Willebrand Disease type 2B (VWD2B)

Quarterly focus

September 25th: Quarterly Focus: highlights in Hodgkin Lymphoma

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. On September 25th, two high-impact international publications on Hodgkin Lymphoma of the past year will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. During this live broadcast you will have the unique opportunity to interact with our expert panel and the authors and ask them your questions. The expert panel consists of: Josée Zijlstra, MD, PhD, hematologist, VUmc Amsterdam Wouter Plattel, MD, PhD, hematologist, UMC Groningen Live video guests: HD18: Prof. Peter Borchmann, MD, PhD, hematologist, University Hospital of Cologne, Germany H10: Prof. Massimo Federico, MD, PhD, medical oncologist, University of Modena and Reggio Emilia, Italy

Congress news

EAHAD 2016: Highlight 2 – Hemophilia A

This highlight is dedicated to hemophilia A. The latest updates of the SIPPET, FranceCoag en RODIN studies are presented and we cover original research. You will learn about PDI, a molecule that might (partly) explain variations in bleeding phenotypes. Also, the value of the TGA test is discussed. The highlight ends with a case discussion, which stresses the importance of a multidisciplinary approach and serves to explain the treatment of inhibitors with ITI. Speakers: Elena Santagostino, MD PhD, Maggiore Hospital Policlinico, Milan: TGA for testing of hemostatic effectiveness of fVIII concentrates in patients with Hemophilia A and inhibitors: in vitro results from the predicTGA study Prof. Cédric Hermans, MD, St-Luc University Hospital, Brussels: Updates on the SIPPET, FranceCoag and RODIN studies: the relationship between specific FVIII concentrate and inhibitor formation Katharina Holstein, MD, University Medical Centre, Hamburg: Expression and release of platelet protein disulfide isomerase (PDI) is increased in patients with hemophilia A Prof. Karin Fijnvandraat, MD, Academisch Medisch Centrum, Amsterdam: Case report - Multidisciplinary approach, treatment of inhibitors with ITI

Congress news

EAHAD 2016: Highlight 1 – Von Willebrand Disease

Two original studies will be covered in the first highlight. In addition, the elements and usefulness of a VWD classification system are discussed. The presenting authors explain why it is important to restage VWD patients using current guidelines, and a controversial topic is breeched: can some VWD2B patients be treated with desmopressin prophylaxis before minor surgery, instead of FVIII concentrate, based on their genotype? Speakers: Carolyn Millar, MD, Hammersmith Hospital, London: The necessity of VWD subclassification Vuokko Jokela, MD, Helsinki University Central Hospital: Impact of platelet function on clinical phenotypes in Von Willebrand Disease: re-evaluation of 83 patient with historical diagnosis Lucia Rugeri, MD, Hôpital Cardiologique, Lyon: Genotyping might help therapeutic decision making in patients with Von Willebrand Disease type 2B (VWD2B)